Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial
Djillali Annane, Sean J. Pittock, Hrishikesh S. Kulkarni, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1051-1063
Open Access | Times Cited: 17

Showing 17 citing articles:

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension
Andreas Meisel, Djillali Annane, Tuan Vu, et al.
Journal of Neurology (2023) Vol. 270, Iss. 8, pp. 3862-3875
Open Access | Times Cited: 50
Thromboinflammation in acute injury: infections, heatstroke, and trauma
Toshiaki Iba, Julie Helms, Marcel Levi, et al.
Journal of Thrombosis and Haemostasis (2023) Vol. 22, Iss. 1, pp. 7-22
Closed Access | Times Cited: 36
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
Frances Hall, Joseph Cheriyan, Andrew P. Cope, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1064-1074
Open Access | Times Cited: 16
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
SARS-CoV-2 enhances complement-mediated endothelial injury via suppression of membrane complement regulatory proteins
Jian Wu, Sanpeng Xu, Zhiqing Li, et al.
Emerging Microbes & Infections (2025)
Open Access
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 4
Complement system activation: bridging physiology, pathophysiology, and therapy
Élie Azoulay, Julien Zuber, Ahmed Aziz Bousfiha, et al.
Intensive Care Medicine (2024) Vol. 50, Iss. 11, pp. 1791-1803
Closed Access | Times Cited: 4
Immunotherapy in the context of sepsis-induced immunological dysregulation
Yiqi Wu, Lu Wang, Yun Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
A complement atlas identifies interleukin-6–dependent alternative pathway dysregulation as a key druggable feature of COVID-19
Karel Van Damme, Levi Hoste, Jozefien Declercq, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 710
Open Access | Times Cited: 9
Plasma protein signatures of adult asthma
Gordon Smilnak, Yura Lee, Abhijnan Chattopadhyay, et al.
Allergy (2024) Vol. 79, Iss. 3, pp. 643-655
Open Access | Times Cited: 1
Immunity and Coagulation in COVID-19
П. П. Авдонин, Maria S. Blinova, Anastasia A. Serkova, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11267-11267
Open Access | Times Cited: 1
Treatment of severe COVID-19: a role for JAK and complement inhibitors?
Antoine Goury, Bruno Mourvillier
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1036-1037
Closed Access | Times Cited: 3
Inhibiting C5 in patients with severe COVID-19—the incorrect target?
Endry H. T. Lim, Alexander P. J. Vlaar, Matthijs C. Brouwer, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 9, pp. e80-e80
Open Access | Times Cited: 2
Future Directions in Therapies for Acute Respiratory Distress Syndrome
Jonathan Millar, Kiran K. Reddy, Lieuwe D. J. Bos
Clinics in Chest Medicine (2024) Vol. 45, Iss. 4, pp. 943-951
Closed Access
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
Pascal Urwyler, Marina Leimbacher, Panteleimon Charitos, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 1
Inhibiting C5 in patients with severe COVID-19—the incorrect target? – Authors’ reply
Djillali Annane, Sean J. Pittock, Derek Dunn, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 9, pp. e81-e81
Closed Access
Targeting C5a is beneficial in critically ill COVID-19 patients
Endry H. T. Lim, Alexander P. J. Vlaar, Matthijs C. Brouwer, et al.
Immunobiology (2023) Vol. 228, Iss. 6, pp. 152743-152743
Open Access
Page 1

Scroll to top